Details of Drug-Drug Interaction
| Drug General Information (ID: DDIDPA3NX9) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Amikacin (liposome) | Drug Info | Plazomicin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antibiotics | Aminoglycosides//Antibiotics | |||||||
| Structure | |||||||||
| Mechanism of Amikacin (liposome)-Plazomicin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Amikacin (liposome) | Plazomicin | |||||||
| Mechanism 1 | Nephrotoxicity | Nephrotoxicity | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Nephrotoxicity | ||||||||
| Factor Description | The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood. | ||||||||
| Mechanism Description |
|
||||||||
| Increased risk of ototoxicity Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Amikacin (liposome) | Plazomicin | |||||||
| Mechanism 2 | Ototoxicity | Ototoxicity | |||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Ototoxicity | ||||||||
| Factor Description | Ototoxicity is the damage to the organs of hearing and/or balance following exposure to drugs or chemicals that affect the inner ear. Ototoxic drugs can impair hearing, balance, or both. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The use of more than one aminoglycoside should be avoided. Patients receiving aminoglycosides should be closely monitored for development of toxicity, including renal function tests and serial, vestibular, and audiometric tests. Ototoxicity may be permanent and may not be apparent until long after therapy has been discontinued. The onset of auditory toxicity may be asymptomatic or may manifest with early symptoms such as feelings of fullness in the ear, high tone hearing loss, or tinnitus. Signs of vestibulotoxicity include ataxia, tinnitus, and vertigo. | ||||||||